Introduction
Genistein is a major soy isoflavone with multiple properties. Epidemiologic studies have shown that long-term routine consumption of soy products has been associated with a lower risk of breast and prostate cancers in some studies (1, 2) . Animal studies also showed that soy/ genistein may have a chemopreventive effect on mammary gland tumor development in both carcinogen-induced rat and at-risk transgenic mouse models (3, 4) . We have reported that dietary phytoestrogens inhibit mammary tumorigenesis in a wt-erbB2 transgenic mouse model (4) . In contrast to this widely accepted preventative role of genistein on breast cancers, however, some studies of breast cancer cells and/or humans have suggested a deleterious or growth-promoting effect by phytoestrogen. In ovariectomized athymic mice implanted with ERþ MCF-7 cells, genistein has been shown to stimulate tumor growth in a dose-dependent manner (5, 6) . We have also reported that a lowdose-isolated isoflavone diet abrogates tamoxifen-mediated chemoprevention in the wt-erbB2 transgenic mouse model (7) . Because of the widespread use of phytoestrogens as supplements or dietary additives, we initiated these cell line studies to obtain a better understanding of the biologic and molecular implications of phytoestrogen administration.
Functional studies suggest that genistein has the properties of a selective ER modulator. Phytoestrogen can bind to both ERs a and b (8) . In ERþ cells, genistein acts as an estrogen agonist at lower concentrations (typically , 5 lM) and an antagonist at higher concentrations (often . 10 lM) (9) . In ERÀ cells, genistein inhibits cell growth in a concentration-dependent manner (10) . Genistein has additional ER-independent actions. It is known to be a strong inhibitor of tyrosine kinase activity in some breast cancer cells (11) . Modulation of the epidermal growth factor receptor (EGFR) has also been associated with genistein-mediated chemoprevention (12) . Genistein has antioxidant and DNA topoisomerase inhibitor functions as well (13, 14) , and it modulates a number of cell cycle and apoptosis regulators, including p21, Bax and Bcl-2 (10) , which leads to cell cycle arrest and apoptosis (15) .
ER and erbB-2 (HER2/neu) are the two most common tumor markers routinely evaluated in breast cancers. Approximately 70% of all breast cancers express ER (16) . ER positivity has been associated with a better prognosis and response to hormonal therapies (16, 17) . ERþ breast cancers have been divided into two subtypes, luminal type A (ERaþ/erbB-2À) and luminal type B (ERaþ/erbB-2þ), on the basis of erbB-2 expression (18, 19) . Luminal type B cases, comprising $10 to 20% of all invasive breast cancers, have a worse prognosis (19) .
erbB-2 is a member of the EGFR family, which also includes EGFR/erbB-1, erbB-3 and erbB-4 (20) . Activation of these receptors leads to the activation of a pleiotropic signaling activity, including the mitogen-activated protein kinase (MAPK)/extracellular signalregulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/ Akt pathways (20) . erbB-2 is amplified and/or overexpressed in $30% of all invasive and up to 50% of in situ breast cancers (21) . erbB-2 alterations have been associated with higher histologic grade, a worse clinical outcome and resistance to some chemotherapeutic and hormonal agents (22) . Although erbB-2 overexpression is generally associated with ER negativity (23, 24) , one-third to half of erbB-2-altered cases coexpress ER (25) . ERþ breast cancers with erbB-2 alterations exhibit cross talk between erbB-2 and ER pathways and may be tamoxifen resistant (26) .
Three-way interactions between dietary phytoestrogens (like genistein), ER and erbB-2 have not been well explored. On one hand, the estrogenic activity of genistein may stimulate ERþ cells via binding to the ER and other mechanisms (27) . On the other hand, genistein-mediated tyrosine kinase inhibitory activity may inhibit the proliferation of erbB-2-overexpressing cells. For erbB-2-expressing ER-negative (erbB-2þ/ERÀ) cells, such as MDA-MB-435/erbB-2, genistein inhibits the growth of these cells through its tyrosine kinase inhibitory activity (28) . As these two mechanisms are opposite, the overall effect of genistein on ERþ and erbB-2-altered breast cancer cells is not clear. Because ERþ/erbB-2-altered breast cancers (termed luminal type B) represent a substantial subset of cancers, which appear to be particularly resistant to some therapies, we sought to examine the effect of genistein on cell proliferation and signal transduction of this subset of breast cancers with an in vitro model system. Age Research, Novato, CA). MDA-MB-435/Neo and MDA-MB-435-erbB-2 (MDA-MB-435-EB1) cells (29) were a gift from Dr Dihua Yu (MD Anderson Cancer Center, Houston, TX). ZR-75-1 and SK-BR-3 cells were obtained from the American Type Culture Collection. The cells were maintained in Dulbecco's modified Eagle's medium/F-12 supplemented with 10% fetal bovine serum and penicillin-streptomycin. For cell starvation experiments in Figures 3 and 4 , 2 Â 10 6 cells were inoculated into each 100 mm dish 24 h before starvation. They were starved in phenol red-free Dulbecco's modified Eagle's medium/F-12 medium containing 0.5% of charcoal-stripped fetal bovine serum for 48 h. The cells were then treated with control or genistein-containing phenol red-free Dulbecco's modified Eagle's medium/F-12 medium for the time indicated in each experiment.
3-(4,5-Dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide assay As described previously (30) , 800 cells were inoculated into each well of a 96-well plate 24 h before treatment. The cells were then treated with drugs at the indicated concentrations for 6 days. After removal of the medium, 50 ll of 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) solution (1500 lg/ml) was added to each well, followed by a 4 h incubation. The MTT solution was replaced by dimethyl sulfoxide. The absorbance was measured at 562 nm using an enzyme-linked immunosorbent assay reader. The data based on eight parallel samples were analyzed using Student's t-test.
Clonogenic assay
Five hundred cells were inoculated into each well of a six-well plate and grown in media containing genistein at indicated concentrations for 14 days. The media were carefully changed every 5 days. At the end point, the media were replaced with the staining buffer (50% ethanol and 0.25% dimethyl-methylene blue) for a 45 min stain. After washing with phosphate-buffered saline, the colonies were counted with the PUV image analysis system. The survival fractions were analyzed with Student's t-test based on three parallel samples.
Western blotting
Cell lysates were prepared as described previously (30) . Fifty micrograms of protein lysate was loaded onto each lane of a gel. Proteins were separated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Membranes were probed with specific primary antibodies at dilutions of 1:300-1:2000. Antibodies against pErk1/2, p21, p27/kip1, cyclin D1, E2F-1, cyclin B1 and Bcl-2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). An antibody against ERa was purchased from Upstate Signaling Solutions (Charlottesville, VA). An anti-phospho-Akt (Ser473) rabbit monoclonal antibody, a phosphor-ERa (Ser118) mouse monoclonal antibody and a phospho-erbB-2 (Tyr1248) were purchased from Cell Signaling Technology (Beverly, MA). After washing, the membranes were probed with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (GE Healthcare, Piscataway, NJ). The specific protein bands were visualized by autoradiography using an enhanced chemiluminescence kit (Pierce Biotechnologies, Rockford, IL).
Cell cycle analysis
Treated cells were trypsinized and washed with phosphate-buffered saline, followed by fixation in 80% of ethanol. After being washed three times with phosphate-buffered saline containing 0.1% Triton X-100, they were treated with ribonuclease A (1 mg/ml) for 30 min and stained with 50 lg/ml propidium iodide. Cell analyses were performed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). The fractions of the total cell population present in the G 1 , S and G 2 -M phases were obtained from DNA histograms by mathematical modeling using MultiFit software (Verity Software House, Topsham, ME).
Luciferase assay
Cells were inoculated into 12-well plates at 1 Â 10 5 per well 24 h before the transfection. Four hundred nanograms of pERE-luciferase construct (a gift from Dr Donald P.McDonnell, Duke University) and 100 ng of pSV-b-gal DNA were transfected into each well using FuGENE 6 Transfection Reagent (Roche, IN). Genistein or 17-b-estradiol was added 16 h after transfection. The cells were harvested 24 h posttransfection, followed by luciferase assay using a kit from Promega (Madison, WI). The chemiluminescence was read using a TD-20/20 Luminometer. b-Galactosidase activity was detected using an Invitrogen kit according to the manufacturer's protocol. The estrogen-responsive element (ERE)-luciferase activity of each sample was normalized with b-galactosidase activity. Results are expressed as fold increase over control luciferase activity normalized by b-galactosidase activity. All experiments were performed in triplicates.
Reverse transcription-polymerase chain reaction Total RNA was isolated from treated cells using the RNeasy mini kit (Qiagen, Valencia, CA). First-strand complementary DNA synthesis was preformed using SuperscriptIIITM First Strand synthesis system (Invitrogen, Carlsbad, CA). The sequences of the primers were as follows: p27 forward: 5#-TGGA-GAAGCACTGCAGAGAC-3# and p27 reverse: 5#-GCGTGTCCTCAGAGT-TAGCC-3#; actin forward: 5#-GCACCACACCTTCTACAATGAGC-3# and actin reverse: 5#-GACGTAGCACAGCTTCTCCTTAATG-3#.
Transfection
Cells from each line were inoculated into six-well plates at 3 Â 10 5 per well 24 h before transfection. pcDNA3/p27 (a gift from Dr Zhen Fan, MD Anderson Cancer Center) or a control vector were transfected into MCF-7/Neo and MCF-7/erbB-2 cells using FuGENE 6 Transfection Reagent.
Results
Genistein induces enhanced growth promotion of ERþ but not ERÀ breast cancer cells that overexpress erbB-2 To study the impact of genistein on breast cancer cells by ER and erbB-2 status, we examined the effect of genistein on two pairs of cancer cell lines with different ER and erbB-2 status. These included the ERa-positive erbB-2 normal MCF-7/Neo cells and erbB-2-transfected MCF-7/erbB-2 cells, as well as the ERa-negative MDA-MB-435/Neo and MDA-MB-435/erbB-2 cells ( Figure 1D ). Although MDA-MB-435 cells are breast cancer cells or melanoma cells remains controversial (31, 32) , these ERÀ cells have been tested for genistein response in previous studies and may serve as control for ERþ MCF-7 cells (28) . When MDA-MB-435/Neo and MDA-MB-435/erbB-2 cells were treated with genistein at concentrations ranging from 0.02 to 50 lM, results from MTT assays show that the responses of both cell lines were in a similar pattern ( Figure 1A ). There was no growth promotion at lower concentrations, and the cells were significantly inhibited at 17 and 50 lM. In contrast, when the ERþ MCF-7/Neo and MCF-7/erbB-2 cells were treated with genistein, the two sublines responded differently across a wide range of doses ( Figure 1B ). Genistein promoted the growth of MCF-7/Neo cells at lower concentrations ( 6 lM) and inhibited their growth at higher concentrations. This is consistent with the biphasic effect of genistein reported by others for ERþ cells (27) . In contrast, the survival fractions of MCF-7/erbB-2 cells treated with 0.02-17 lM of genistein were higher than MCF-7/Neo cells under the same conditions. The difference between the two cell lines was more evident in 6 and 17 lM of groups. These results suggest that genistein may induce enhanced growth promotion at lower concentrations and reduced inhibition at higher concentrations in ERþ/erbB-2þ breast cancer cells. In support of this notion, our results also showed that spontaneous erbB-2-overexpressing breast cancer cell lines with different ER statuses responded differently to genistein, as indicated by more genistein resistance in ERþ/erbB-2þ ZR-75-1 cells than ERÀ/erbB-2þ SK-BR-3 cells ( Figure 1C ). To confirm the MTT results, we examined the effect of genistein on MCF-7/ Neo and MCF-7/erbB-2 cells using clonogenic assays. As shown in Figure 1E , survival factions of the two cell lines based on colony numbers also indicate that MCF-7/erbB-2 cells had more proliferative advantages over MCF-7/Neo cells. Of note, the colonies of genisteintreated MCF-7/erbB-2 cells were also larger than the control cells under the same conditions, suggesting a faster proliferation.
The induction of cells into S phase by genistein is enhanced by erbB-2
To further characterize the genistein-mediated growth promotion of ERþ MCF-7 cells, we compared the cell cycle distribution of MCF-7/ Neo and MCF-7/erbB-2 cells by flow cytometry ( Figure 1F ). After 48 h of genistein treatment, the percentage of MCF-7/Neo cells in the S phase decreased modestly in response to 5-10 lM of genistein. In contrast, treatment of the MCF-7/erbB-2 cells with 5-10 lM of genistein resulted in more cells in the S and G 2 /M phases. These data are consistent with our MTT results, which showed growth promotion by genistein in the erbB-2-transfected MCF-7 cells.
Genistein induces enhanced tamoxifen resistance in MCF-7/erbB-2 cells erbB-2 alterations have been associated with tamoxifen resistance in ERþ breast cancer patients (23) . We have previously reported that
genistein interferes with tamoxifen-mediated growth inhibition of MCF-7 cells (7) and that this deleterious interaction can be reduced by increasing the concentrations of either tamoxifen or genistein. To investigate whether coexpression of erbB-2 modifies this response, we studied the cell growth/inhibition of MCF-7/erbB-2 and MCF-7/Neo cells treated with genistein or tamoxifen alone or in combination, as compared with untreated control. As shown in Figure 2 , genistein alone induced enhanced growth promotion of both cell lines at concentrations of 2-10 lM, but it was more evident in MCF-7/erbB-2 cells. In the absence of genistein, 0.4 lM of tamoxifen inhibited the growth of MCF-7/Neo and MCF-7/erbB-2 cells to 71 and 85% of the untreated control, respectively. The combination of tamoxifen with 2 or 10 lM of genistein, however, abrogated tamoxifen's inhibitory effect in both cell lines. In particular, the increases in the proliferation rate between tamoxifen alone and combined treatment in MCF-7/ erbB-2 cells were significantly greater than MCF-7/Neo cells under the same conditions. These results suggest that genistein may be a critical risk factor that undermines tamoxifen efficacy in ERþ/ erbB-2þ breast cancers.
Genistein induces enhanced ER activity in MCF-7/erbB-2 cells
The enhanced growth promotion and tamoxifen resistance in genisteintreated control and erbB-2-overexpressing MCF-7 cells suggest that the estrogenic effects of genistein may override its inhibitory effects on tyrosine kinase activity. To evaluate the role of the ER pathway activation in genistein-treated cells by erbB-2, we performed an ERE-luciferase assay on both the MCF-7/Neo and the MCF-7/erbB-2 cells under a variety of treatment conditions. As Genistein and ER positive/erbB-2 overexpressing breast cancer shown in Figure 3A , 10-20 lM genistein induced greater ERE activity than 10 nM of E2 in both cell lines. ERE induction by genistein was significantly greater in MCF-7/erbB-2 cells as compared with MCF-7/Neo cells (50-fold in MCF-7/Neo; .150-fold in MCF-7/erbB-2).
We next studied whether the modulation of tamoxifen resistance by genistein involved activation of ER-dependent signaling. Genistein alone (at 15 lM) induced a 50-to 100-fold increase in ERE activity in the MCF-7/Neo and MCF-7/erbB-2 cells, whereas tamoxifen (3 lM) alone induced no significant estrogenic activity in either cell line ( 3-fold increase of ERE-luciferase activity; Figure 3B ). When genistein and tamoxifen were administered simultaneously, the activation of the ERE was remarkably profound in both cell lines, particularly in ERþ/erbB-2-expressing cells. These data suggest that the interaction between genistein and tamoxifen is more deleterious in these cells.
Because increased ER-dependent activity (ERE activation) could result from an increase in ER expression and/or functional modulation of the receptor, we compared the protein levels of ERa in nonsynchronized and serum-starved MCF-7/Neo and MCF-7/erbB-2 cells, in the presence or absence of genistein ( Figure 3C ). In general, ERa protein levels were lower in MCF-7/erbB-2 cells as compared with control MCF-7/Neo cells regardless of the culture conditions. Starvation downregulated ER levels in both cell lines. We next examined ERa phosphorylation, using a phospho-Ser118-specific antibody. The data show that phosphorylated ERa levels were higher in MCF-7/erbB-2 cells, as compared with MCF-7/neo cells under both starved and non-synchronized conditions ( Figure 3C ). Genistein treatment, especially after starvation, induced enhanced ERa phosphorylation in MCF-7/erbB-2 cells. Given that the total protein levels of ERa were lower in genisteintreated MCF-7/erbB-2, as compared with control cells, the phosphorylation status of ERa may be pivotal to the regulation of genistein-mediated ER signaling.
Activation of erbB-2, PI3K and MAPK pathways in genistein-treated MCF-7/erbB-2 cells
Increased phosphorylation of ERa in genistein-treated MCF-7/erbB-2 cells suggests elevated tyrosine kinase activity in these cells. However, previous studies have shown that genistein is a potent inhibitor of tyrosine kinase activity, especially for the related receptor EGFR (33) , and that erbB-2 can be activated by heterodimer formation with EGFR (22) . To investigate the effect of genistein on receptor tyrosine kinase activity in our cell lines, we examined erbB-2 activation in genistein-treated cells. As shown in Figure 3C , genistein induced erbB-2 phosphorylation in the ERþ MCF-7/erbB-2 cells with or Fig. 2 . Genistein induces enhanced tamoxifen resistance in MCF-7/erbB-2 cells. MCF-7/Neo and MCF-7/erbB-2 cells were inoculated into 96-well plates at 800 per well. The cells were then treated with genistein (0, 2, 10 or 50 lM G), tamoxifen (0 or 0.4 lM) alone or in combination for 6 days. Cell survival/proliferation was measured using MTT assay as detailed in the Materials and Methods. The increases in the proliferation rate between tamoxifen alone and combined treatment of each cell line were compared and analyzed using Student's t-test; ÃÃ P , 0.01. After the transfection of the reporter plasmids, the cells were treated with 0.1% of dimethyl sulfoxide (Con), 3 lM of tamoxifen (T or Tam), 15 lM of genistein (G) alone or in combination (T þ G), followed by ERE-luciferase activity analysis. (C) Total ERa, erbB-2, pERa, and perbB-2 levels in control and genistein-treated MCF-7/Neo and MCF-7/erbB-2 cells. The cells were either non-synchronized or starved in phenol red-free Dulbecco's modified Eagle's medium supplemented with 0.5% of charcoal-stripped fetal bovine serum for 48 h followed by 24 h treatment with 10 lM of genistein or 0.1% of dimethyl sulfoxide. Total ERa, erbB-2, pERa/Ser118 and perbB-2/Tyr1248 were detected using western blot.
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without starvation. These results suggest that genistein may act as a receptor tyrosine kinase agonist, rather than a tyrosine kinase inhibitor, in cells with coexpression of ER and erbB-2. Since MAPK/ERK and the PI3K/Akt signaling are major pathways downstream of erbB-2 activation, we examined the activation of the two pathways in genistein-treated cells. To this end, the paired cell lines were starved for 48 h followed by treatment with 0, 2 or 10 lM of genistein in phenol red-free medium for 45 min. As shown in Figure 4A , genistein treatment induced the activation/phosphorylation of Akt and ERK1/2 in both cell lines. More importantly, activation of the PI3K/Akt and MAPK/ERK pathways, as indicated by pAkt1 and p-Erk2 levels, was significantly enhanced in MCF-7/ erbB-2 cells. Consistent with Akt and ERK1/2 activation, phosphorylation of ERa was also enhanced in MCF-7/erbB-2 cells. These results correlate ERa phosphorylation/activation with the activation of Akt and MAPK pathways and suggest that ER-erbB-2 cross talk may be the mechanism that abrogates genistein's tyrosine kinase inhibitor activity in these cells.
To assess the functional role of MAPK and PI3K pathways in genistein-mediated growth promotion in these cells, we next examined the effects of genistein on the proliferation of MCF-7/ Neo and MCF-7/erbB-2 cells in the presence or absence of LY294002 and PD098059 (specific inhibitors of the PI3K and MAPK pathways, respectively). As shown in Figure 4B , both LY294002 and PD098059 abrogated the genistein-mediated growth promotion of the MCF-7/erbB-2 cells. These data show that genistein-associated cellular proliferation involves the activation of both the PI3K and the MAPK pathways in erbB-2-overexpressing ERþ MCF-7 cells.
Downregulation of p27/kip1 is associated with genistein-induced enhancement of growth promotion in MCF-7/erbB-2 cells To identify the cell cycle regulators that are associated with the modified cell cycle progression in genistein-treated MCF-7/erbB-2 cells, we examined the protein levels of p53, p21, p27/kip1, E2F-1, cyclin B1, cyclin D1 and cdc-2 in both cell lines treated with genistein. Of the markers examined, p27/kip1 downregulation was the most notably modified by genistein treatment in MCF-7/erbB-2, as compared with MCF-7/Neo cells ( Figure 5A ). p27/Kip1 is a cdk inhibitor that controls cell cycle progression at the G 1 checkpoint. A decrease in p27/ kip1 expression should result in enhanced proliferation. This is consistent with Figure 1F (flow data), where genistein treatment of the MCF-7/erbB-2 cells resulted in an increased percentage of cells in S phase. In contrast, the MCF-7/Neo cells showed a decrease in S, G 2 /M cells with genistein treatment. Figure 3C , followed by treatment with 0 (0.1% dimethyl sulfoxide), 2 or 10 lM of genistein for 45 min. Protein levels of pErk1/2/Thr202/Tyr204, tErk2, pAkt1/Ser473, tAkt1 tERa and pERa/ Ser118 were probed with antibodies against each specific form of protein.
(B) Blocking PI3K and/or MAPK pathways abrogates genistein-induced growth promotion. The cells in 24-well plates at 4000 per well were treated with 0.01% dimethyl sulfoxide (Con), 10 lM of genistein (G), 50 lM of LY294002 (LY), 50 lM of PD098059 (PD) or in combination (G/LY, G/PD) for 4 days. The survival fractions were measured using MTT assay and analyzed using Student's t-test;
Ã P , 0.05, ÃÃ P , 0.01. (C) Herceptin (anti-erbB-2) inhibits p27 downregulation in genisteintreated ERþ/erbB-2þ BT-474 cells. The cells were treated with Herceptin (10 lg/ml) and genistein (12.5 lM) alone or in combination for 48 h, followed by western blot detection of p27.
Genistein and ER positive/erbB-2 overexpressing breast cancer
To explore the mechanism by which genistein mediates downregulation of p27 in MCF-7/erbB-2 cells, we examined p27 messenger RNA and protein levels at various concentrations of genistein. We found that genistein induced downregulation of p27/kip1 protein without significant alteration of its messenger RNA levels in MCF-7/ erbB-2 cells. In contrast, neither p27/kip1 protein nor messenger RNA levels were modified by genistein in control MCF-7/Neo cells ( Figure 5B1 and B2) . These data indicate that modulation of p27/ kip1 expression in genistein-treated ERþ/erbB-2 cells is primarily at the protein level and suggest that altered regulation of p27/kip1 protein stability may be the major mechanism. To demonstrate that genistein also induces p27/kip1 downregulation in other ERþ/erbB-2þ cells and test whether genistein-induced downregulation can be blocked by anti-erbB-2 agent Herceptin, we detected p27 levels in BT-474 cells, a known ERþ/erbB-2 breast cancer cell line, treated with genistein or Herceptin alone or in combination. Genistein induced striking downregulation of p27/kip1 in BT-474 cells ( Figure 5C ). However, genistein-mediated p27/kip1 downregulation was only partially rescued by Herceptin. While confirming our findings in MCF-7 cells, these results also suggest that other pathways may also be involved in genistein-mediated downregulation of p27/kip1 in ERþ/ erbB-2þ breast cancer cells.
Overexpression of p27/kip1 attenuates genistein-mediated growth promotion in MCF-7/erbB-2 cells To test whether genistein-induced downregulation of p27/kip1 in MCF-7/erbB-2 cells contributes to the enhanced proliferation of these cells, we transfected p27 complementary DNA and control vector into MCF-7/Neo and MCF-7/erbB-2 cells, respectively, followed by genistein treatment and cell cycle analysis ( Figure 6A ). Overexpression of p27 decreased the percentage of cells in S phase in each cell line treated with genistein, as compared with the cells transfected with control vector ( Figure 6B ). However, the decrease was more significant in MCF-7/erbB-2 cells. These results support a functional correlation between altered p27/kip1 regulation and genistein-mediated growth promotion in MCF-7/erbB-2 cells.
Discussion
In this study, we focused on the biologic and molecular effects of genistein on ERþ/erbB-2 breast cancer cells. This phenotype (known in the literature as luminal type B) comprises 10-20% of breast cancers (19) . Previous studies have shown that genistein may stimulate the growth of ERþ MCF-7 cells and xenograft tumors, but it induces persistent inhibition of ERÀ/erbB-2þ cancer cells (5, 28) . The responses of cells coexpressing ER and erbB-2 to genistein, tamoxifen or genistein plus tamoxifen, however, have not been explored but probably have significant translational value.
Results from this study demonstrate that genistein may induce enhanced growth promotion and tamoxifen resistance in ERþ/erbB-2 breast cancer cells. We further demonstrate that genistein induces enhanced signaling in both ER and erbB-2 pathways, as indicated by increased activation of ERE activity and enhanced phosphorylation of ERa, erbB-2, Akt1 and ERK1/2 in MCF-7/erbB-2 cells. Since ER activation may upregulate growth factors/growth factor receptors (34, 35) and activation of erbB-2/EGFR may induce ERa activation/ phosphorylation (36, 37) , our data suggest that genistein-associated growth promotion and tamoxifen resistance in ERþ/erbB-2þ breast cancer cells involve ER-erbB-2 cross talk. This is consistent with the studies showing that ER-erbB-2 cross talk plays a critical role in tamoxifen resistance in breast cancer treatment (38) . Although genistein is also known to be a tyrosine kinase inhibitor and erbB-2-overexpression-associated tyrosine kinase activity could be a target of genistein, our data demonstrate that genistein at lower doses induces estrogenic activity that overrides its tyrosine kinase inhibitor activity in ERþ/erbB-2þ cells. This suggests that ER status is a critical determinant of genistein-associated tyrosine kinase inhibitor activity and both ERa and erbB-2 are important factors that can modify the effects of genistein on breast cancer cells.
Genistein-induced downregulation of p27 in MCF-7/erbB-2 cells is another important finding in this study. It is known that p27/kip1 is a critical inhibitor of cyclin-dependent kinases that binds to and inhibits the activities of cdk2-cyclin E and cdk2-cyclin A complexes to block cell cycle progression at the G 1 -S transition (39) . Downregulation of p27/kip1 would allow more cells entry into the S phase. We found that genistein induces striking downregulation of p27/kip1 in MCF-7/erbB-2 cells but not in MCF-7/Neo cells, suggesting a specific interaction between genistein and erbB-2 and its contribution to growth promotion in MCF-7/erbB-2 cells. This is supported by the results showing that overexpression of p27/kip1 in these cells inhibits genistein-mediated growth promotion in both MCF-7/Neo and MCF-7/erbB-2 cells (Figure 6 ). Moreover, we found that downregulation of p27/kip1 in genistein-treated MCF-7/erbB-2 cells was primarily at the protein level. This is consistent with the report that downregulation of p27/kip1 in erbB-2-altered cells can result from increased Akt activity via phosphorylation of p27/kip1 at threonine 157 (40) , which causes its translocation from the nucleus to the cytoplasm and results in changes in p27/kip1 stability and degradation through the ubiquitin pathway (40, 41) . However, since genistein-induced p27 downregulation in BT-474 cells was only partially rescued by Herceptin ( Figure 5C ) and p27/kip1 can also be regulated through other signaling pathways (42) , p27/kip1 downregulation in genistein-treated cells may involve the modulation of other factors/pathways, which warrants further investigation. Taken together, our results suggest that genistein at lower concentrations may induce growth promotion and tamoxifen resistance in ERþ/erbB-2þ cells, as compared with ERÀ cells and ERþ/erbB-2 normal cells. The molecular mechanisms involve the activation of ER-erbB-2 cross talk, including increased activation of ER-associated transcription, MAPK/ERK1/2 pathway, PI3K/Akt pathway and the downregulation of p27/kip1 in these cells. Signaling downstream of these pathways would lead to enhanced proliferation. Moreover, marked higher survival fractions in MCF-7/erbB-2 cells treated with 6-17 lM of genistein, as compared the MCF-7/Neo cells ( Figure 1B and E), suggest that the reduced inhibition in these cells may also involve inhibition of apoptosis in these cells, which will be examined in future studies.
Given the widespread use of soy/genistein products and the possible deleterious effects, our data have translational relevance to patient care. Although soy might be beneficial to tumor prevention under certain conditions, it may be a potent risk factor in some cases. Our data suggest that ERþ/erbB-2þ invasive breast cancers in particular may be most vulnerable to soy/genistein-associated risk (25) . In addition, since ER and erbB-2 are overexpressed in the majority of ductal carcinomas in situ (43) , interaction in these patients may also occur. Therefore, our study alerts patients with ERþ/erbB-2þ breast cancers and tamoxifen taking or at-risk women exposed to genistein, either by supplement or by involuntarily.
Results from this in vitro study have provided proof of principle of the impact of soy/genistein on ERþ/erbB-2þ breast cancer cells. For the interpretation of these in vitro data, it should be noted that the threshold for low and high dosages varies depending on treatment conditions and in vitro or in vivo settings. Although in vivo genistein concentrations are rarely .4 lM (44), the threshold for in vitro studies usually refers to 5-10 lM (45). In this study, genistein treatment in most tests was in the presence of 10% fetal bovine serum, and genistein-mediated inhibition was mainly observed at concentrations .10 lM in this study (up to 20 lM for MCF-7/erbB-2 cells). Low doses here are referred to the concentrations in the stimulating phase. To solve the discrepancy between in vitro and in vivo concentrations issue, we have recently performed animal studies to examine the effect of soy/genistein on mammary tumor development in mouse mammary tumor virus-erbB-2 transgenic mice. We found that exposure to soy-rich diet Purina-5001 after 20 weeks promoted mammary tumor development in these animals, and this was preceded by increased activation of ER and erbB-2 pathways in the mammary tissues (Xiaohe Yang, Zhikun M and Shihe Yang, manuscript in preparation). Since non-transformed mammary tissues in these mice are ERþ/ erbB-2þ (46) , the data are consistent with the in vitro results. These in vivo data support the notion that physiological concentration of soy/ genistein may stimulate erbB-2-overexpressing mammary tumor/ cells, which underscores the possible impact of soy/genistein on breast cancer survivors or women at risk.
In summary, we have found that genistein induces enhanced growth promotion and tamoxifen resistance in ERþ/erbB-2 cells. ERþ/ erbB-2 breast cancers might be most vulnerable to soy/genisteinassociated risk. The underlying mechanisms involve enhanced activation of ER signaling and MAPK/PI3K pathways, indicating a cross talk between ERa and erbB-2 pathways. We also found that genistein induces striking downregulation of p27/kip1 protein in MCF-7/ erbB-2 cells and that overexpression of p27/kip1 attenuated genistein-mediated growth promotion, suggesting that p27 may be a critical target and marker for genistein-induced growth promotion. Given that ERþ/erbB-2-overexpressing tumors count for a substantial group of breast cancers and the widespread exposure of women to soy/genistein, our findings are valuable in breast cancer risk control and management. 
